MX2019001978A - Compuestos antibioticos. - Google Patents

Compuestos antibioticos.

Info

Publication number
MX2019001978A
MX2019001978A MX2019001978A MX2019001978A MX2019001978A MX 2019001978 A MX2019001978 A MX 2019001978A MX 2019001978 A MX2019001978 A MX 2019001978A MX 2019001978 A MX2019001978 A MX 2019001978A MX 2019001978 A MX2019001978 A MX 2019001978A
Authority
MX
Mexico
Prior art keywords
compounds
antibiotic compounds
gram
infection
treatment
Prior art date
Application number
MX2019001978A
Other languages
English (en)
Inventor
Meo Paul
Khan Nawaz
Original Assignee
Discuva Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Discuva Ltd filed Critical Discuva Ltd
Publication of MX2019001978A publication Critical patent/MX2019001978A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a compuestos antibióticos de fórmula (I), a composiciones que contienen estos compuestos y a métodos para tratar enfermedades bacterianas e infecciones usando los compuestos. Los compuestos encuentran su aplicación en el tratamiento de la infección con, y en las enfermedades causadas por bacterias Gram-positivas y/o Gram-negativas, y en particular en el tratamiento de infecciones con y enfermedades causadas por, Neisseria gonorrhoeae. (ver Fórmula I).
MX2019001978A 2016-08-22 2017-08-22 Compuestos antibioticos. MX2019001978A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1614314.1A GB201614314D0 (en) 2016-08-22 2016-08-22 Antibiotic compounds
PCT/GB2017/052478 WO2018037223A1 (en) 2016-08-22 2017-08-22 Antibiotic compounds

Publications (1)

Publication Number Publication Date
MX2019001978A true MX2019001978A (es) 2019-08-01

Family

ID=57045563

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019001978A MX2019001978A (es) 2016-08-22 2017-08-22 Compuestos antibioticos.

Country Status (15)

Country Link
US (1) US20190194179A1 (es)
EP (1) EP3500567A1 (es)
JP (1) JP2019528291A (es)
KR (1) KR20190046894A (es)
CN (1) CN109923111A (es)
AU (1) AU2017316742A1 (es)
BR (1) BR112019003427A2 (es)
CA (1) CA3034000A1 (es)
CO (1) CO2019002624A2 (es)
EA (1) EA201990551A1 (es)
GB (1) GB201614314D0 (es)
MX (1) MX2019001978A (es)
PH (1) PH12019500360A1 (es)
SG (1) SG11201901374WA (es)
WO (1) WO2018037223A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3636645A1 (de) 2018-10-11 2020-04-15 Bayer Aktiengesellschaft Verfahren zur herstellung schwefel-substituierter pyridinderivate
WO2020074558A1 (de) 2018-10-11 2020-04-16 Bayer Aktiengesellschaft Verfahren zur herstellung von imidazolderivaten
CA3127532A1 (en) 2019-01-24 2020-07-30 Daiichi Sankyo Company, Limited 4,5,6,7-tetrahydro[1-3]thiazolo[5.4-c]pyridine-2-yl urea compounds and use of thereof as sirtuin activators
WO2020172206A1 (en) * 2019-02-22 2020-08-27 Agile Sciences, Inc. Compositions providing enhanced antibacterial activity against gram-positive bacteria and use thereof
CN111808093B (zh) * 2019-04-12 2023-05-16 中国医学科学院医药生物技术研究所 一种新德里金属-β-内酰胺酶-1抑制剂
CA3135615A1 (en) * 2019-04-12 2020-10-15 Mitobridge, Inc. Hmox1 inducers
CN113185475A (zh) * 2021-04-29 2021-07-30 江苏永凯化学有限公司 一种高效低污染的精恶唑禾草灵生产工艺
WO2023234970A1 (en) * 2022-06-01 2023-12-07 KUDA Therapeutics, Inc. Imidazopyridine and oxazolopyridine derivatives and analogs thereof, methods of preparation thereof, methods of hif-1/2a pathway inhibition, and induction of ferroptosis
CN117003710A (zh) * 2023-07-19 2023-11-07 镇江先锋植保科技有限公司 一种2-巯基-6-氯苯并恶唑的制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8604217B2 (en) * 2009-11-12 2013-12-10 Selvita S.A. Compound, a process for its preparation, a pharmaceutical composition, use of a compound, a method for modulating or regulating serine/threonine kinases and a serine/threonine kinases modulating agent
JP5786402B2 (ja) * 2011-03-29 2015-09-30 コニカミノルタ株式会社 光学フィルム、及びそれを用いた偏光板、液晶表示装置
WO2016039939A1 (en) * 2014-09-09 2016-03-17 Ptc Therapeutics, Inc. Bicyclic and tricyclic substituted 2-pyridinone antibacterial compounds

Also Published As

Publication number Publication date
BR112019003427A2 (pt) 2019-05-21
EA201990551A1 (ru) 2019-12-30
KR20190046894A (ko) 2019-05-07
US20190194179A1 (en) 2019-06-27
WO2018037223A1 (en) 2018-03-01
CN109923111A (zh) 2019-06-21
GB201614314D0 (en) 2016-10-05
CA3034000A1 (en) 2018-03-01
SG11201901374WA (en) 2019-03-28
AU2017316742A1 (en) 2019-04-11
CO2019002624A2 (es) 2019-05-31
EP3500567A1 (en) 2019-06-26
PH12019500360A1 (en) 2019-11-11
JP2019528291A (ja) 2019-10-10

Similar Documents

Publication Publication Date Title
PH12019500360A1 (en) Antibiotic compounds
PH12016501577A1 (en) Monobactam organic compounds for the treatment of bacterial infections
MX2018001075A (es) Agentes terapeuticos y profilacticos antibacterianos.
PH12016501512B1 (en) Treatment for resistant acne
PH12016502436A1 (en) Anti-infective compounds
PH12017501019A1 (en) Isoxazole hydromaxamic acid compounds as lpxc inhibitors
NZ593111A (en) Antibacterial compounds
ZA202002093B (en) Antibacterial compounds
MX2015007556A (es) Derivados de manosa para tratar infecciones bacterianas.
MX2019007613A (es) Terapia de combinacion con compuestos ?-lactamicos sustituidos con amidina e inhibidores de ?-lactamasa para infecciones con cepas bacterianas resistentes a antibioticos.
MX2017012545A (es) Compuestos heterociclicos y su uso en la prevencion o tratamiento de las infecciones bacterianas.
NZ724798A (en) Polymyxin derivatives as antimicrobial compounds
WO2018208987A3 (en) Antibacterial compounds
MX2021003084A (es) Compuestos antibacterianos.
MX2017009094A (es) Derivado de polimixina y usos del mismo.
WO2017218922A3 (en) Compositions and methods for the treatment of bacterial infections
ZA202006612B (en) Antibacterial compounds
MX2017012073A (es) Compuestos de minociclina para biodefensas.
MX2017012535A (es) Compuestos hetorociclicos novedosos y su uso en la prevencion o tratamiento de las infecciones bacterianas.
WO2015024021A3 (en) Antibacterial compounds
PH12016501532A1 (en) Antibacterial combinations comprising polymyxin
NZ737820A (en) Mannose derivatives for treating bacterial infections
MX2017012539A (es) Compuestos heterociclicos y su uso en la prevencion o tratamiento de las infecciones bacterianas.
EA201892278A1 (ru) Анбитактериальные биароматические производные с оксетан-3-илокси замещением
MX2019009362A (es) Compuestos heterociclicos novedosos y sus usos en la prevencion o el tratamiento de infecciones bacterianas.